|Bid||3.05 x 1800|
|Ask||3.50 x 400|
|Day's Range||3.10 - 3.20|
|52 Week Range||2.55 - 26.95|
|PE Ratio (TTM)||-1.67|
|Earnings Date||Oct 25, 2017 - Oct 30, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.75|
NEW HAVEN, Conn., Sept. 25, 2017-- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced that it will be making ...
NEW YORK , Sept. 7, 2017 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...
CHAPEL HILL, N.C., Sept. 07, 2017-- Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical ...